Table 1.

Characteristics of High-Lp(a) subjects: Number of subjects: 39 (females = 25, on lipid-lowering medications = 25). RLU=Relative Light Units.

	Minimum	Median	Maximum	Mean	Std. Deviation	Std. Error of Mean
Age	20	62	83	58.9	16	2.3
Lp(a) (mg/dl)	39	98	320	132	78	13
Apo(a) nM	117	219	664	270	146	25
Average Kringle IV2 repeats	3.8	10	27	11	5.2	0.8
ApoA-I (mg/dl)	65	118	208	117	27	4.3
ApoA-II (mg/dl)	13	30	86	32	16	2.5
ApoA-IV (mg/dl)	5.5	13	45	16	10	1.7
apoB (mg/dl)	52	173	313	183	71	11
ApoC-I (mg/dl)	0.2	2.8	12	3.2	2.7	0.4
ApoC-II (mg/dl)	1.0	2.9	11	3.5	1.9	0.3
ApoC-III (mg/dl)	2.9	10	17	9.8	3.8	0.6
ApoE (mg/dl)	3.5	9.7	18	9.3	3.3	0.5
ApoM (mg/dl)	0.5	1.2	2.0	1.3	0.4	0.06
LDL (mg/dl)	54	141	257	140	48.5	7.8
PCSK9 (ng/ml)	168	438	916	464	197	31.6
Lp(a)-bound PCSK9 (RLU)	713	1834	8924	2622	1943	343
Fold increase in PCSK9 on Lp(a) compare to LDL	0.2	1.7	9.2	2.4	2.1	0.4